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Abstract
The preparation of novel multi-substituted 1,2,3-triazole-modified β-aminocyclohexanecarboxylic acid derivatives in a simple and
efficient continuous-flow procedure is reported. The 1,3-dipolar cycloaddition reactions were performed with copper powder as a
readily accessible Cu(I) source. Initially, high reaction rates were achieved under high-pressure/high-temperature conditions. Subse-
quently, the reaction temperature was lowered to room temperature by the joint use of both basic and acidic additives to improve
the safety of the synthesis, as azides were to be handled as unstable reactants. Scale-up experiments were also performed, which led
to the achievement of gram-scale production in a safe and straightforward way. The obtained 1,2,3-triazole-substituted β-aminocy-
clohexanecarboxylates can be regarded as interesting precursors for drugs with possible biological effects.
Introduction
In recent years, triazole-containing compounds have become
potential targets for drug discovery [1,2]. A large number of
1,2,3-triazoles exhibit various biological effects [3], e.g.,
antiviral (1), antibacterial (2), antifungal (3) and anticancer (4)
activities [4-7] (Figure 1). The 1,2,3-triazole skeleton is
frequently used as a pharmacophore for the modification of
known pharmaceuticals. Triazole analogues of several bioac-
tive compounds have recently been reported. Examples are
those of the well-known highly functionalized antiviral cyclic
amino acid derivatives oseltamivir and zanamivir (5 and 6 in
Figure 1) [8,9]. The 1,2,3-triazole moiety is a constituent part of
many modified nucleosides or carbanucleosides with antiviral,
anti-HIV or cytostatic activities [10-12]. However, the scope of
triazole chemistry is not confined to drug discovery. There are
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an increasing number of applications in numerous other areas of
modern chemical sciences, such as bioconjugation [13], supra-
molecular chemistry, [14] and polymer sciences [15].
Figure 1: Examples of 1,2,3-triazoles with various biological activities.
Probably the most useful and powerful procedure for the syn-
thesis of 1,2,3-triazoles is the Huisgen 1,3-dipolar cycloaddi-
tion of organic azides with acetylenes [16]. The classical
Huisgen reaction, thermally induced, gives an approximate 1:1
mixture of 1,4- and 1,5-disubstituted 1,2,3-triazole isomers
(Scheme 1) [17]. However, when Cu(I) catalysis is applied, the
reaction becomes regioselective, exclusively yielding the 1,4-
regioisomer within a relatively short reaction time [18-20].
Recently, Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC)
has become the basis of the so-called click chemistry concept
due to its wide applicability and efficiency.
Over the past twenty years, alicyclic β-amino acids have
attracted great interest among synthetic chemists, thanks to their
massive pharmacological potential [21,22]. For example,
cispentacin ((1R,2S)-2-aminocyclopentanecarboxylic acid, 7) is
a widely investigated naturally occurring carbocyclic β-amino
acid with strong antifungal properties against Candida species
(Figure 2) [23]. Its synthetic 4-methylene derivative
icofungipen (8), also an antifungal agent, is now proceeding
Scheme 1: 1,3-Dipolar azide–alkyne cycloadditions.
through clinical development for the oral treatment of yeast
infections (Figure 2) [24]. Certain multi-substituted cyclo-
hexane amino acid derivatives, such as oryzoxymycin (9) and
tilidine (10), are also well-known bioactive agents with anti-
cancer, antibacterial, antiviral or analgesic effects (Figure 2)
[25,26]. The alicyclic β-amino acids are key intermediates for
the synthesis of a series of pharmaceutically relevant products
[27], such as amino esters, amino alcohols, azides and hetero-
cycles. Moreover, they are frequently used as building blocks
for the synthesis of new peptides and foldamers with possible
biological effects [28].
Figure 2: Selected bioactive alicyclic β-amino acids.
Modern continuous-flow (CF) technologies offer many advan-
tages over classical batch-based procedures [29-32], including
efficient mixing quality [33], excellent heat and mass transfer
[34], shorter reaction times [35-37], reduced reagent consump-
tion [38-40], improved safety [41,42], and operational
simplicity [43]. Furthermore, CF methodologies provide oppor-
tunities for a simple and rapid scale-up [44,45] and automation
[46,47] of chemical processes. They also tend to be environ-
mentally benign technologies [48]. In consequence of these
benefits, flow chemistry-based techniques have exerted a
significant impact on modern synthetic chemistry, ranging from
laboratory-based experiments to industrial-scale production.
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Here, we describe a safe and efficient CF synthesis of a series
of novel 1,2,3-triazole-modified β-aminocyclohexanecar-
boxylic acid derivatives as potential biologically active com-
pounds. Gram-scale production is also reported, which predicts
a possible usefulness for the pharmaceutical industry.
Results and Discussion
Several approaches are to be found in the literature for the
Cu(I)-catalysed flow synthesis of triazoles. Heterogeneous
Cu(I) sources are most popular, such as copper-in-charcoal
(Cu/C) [49,50], solid supported Cu(I) species [51-54], and
heated copper wirings [55-58], but a homogeneous technique
has also recently emerged [59]. The main driving forces behind
these CF methodologies are the safety aspects associated with
the handling of azides and the inherent scalability of flow
processing. Moreover, when organic azides are formed in situ,
operational safety can be further improved [55,57]. We envi-
sioned that it would be simplest to make use of copper powder
as a catalytic source [60]. Similarly to cases when heated rings
of copper wire are employed, a copper surface acts as a source
of active copper species. Copper is constantly oxidized when
exposed to air, and non-self-protecting layers of different
oxides, including Cu2O, are formed on its surface [61], which
can promote CuAAC. Thus, we utilized copper powder in a
stainless steel column, which served as a catalyst bed later on.
The catalyst bed was placed into a stainless steel block with a
Peltier heating system, which could heat the column up to
100 °C. A backpressure regulator was also integrated to ensure
pressures up to 100 bar. The mixture of the reactants was
pumped through the system continuously by means of an HPLC
pump. This experimental setup is practical and cheap, as it does
not require costly catalysts or special apparatus. At the same
time this setup is safe, even with unstable reactants such as
azides (Figure 3).
To maximize the CF triazole synthesis reaction rates, it
appeared easiest to use high-temperature conditions initially.
The application of elevated pressure in CuAAC is also benefi-
cial, as it can promote the product formation in accordance with
Le Chatelier’s principle [60] and also prevents the solvent from
boiling over when high temperature is used. Thus, 100 °C and
100 bar were selected as conditions A for the CF synthesis.
However, when azides are reacted, it is important to minimize
the explosion hazard. Accordingly, we attempted to improve the
rates of the reaction in the presence of additives, without the use
of high temperature [60]. Amines are known to accelerate
CuAAC, in particular by coordinating to catalytically active
Cu(I) species and promoting their liberation from the copper
matrix [62,63]. It was recently shown that the use of certain
acids as additives is also beneficial, as this can further accel-
erate the formation of the triazole product [64-66] and also
Figure 3: Experimental setup for the CF reactions.
prevents the accumulation of unwanted byproducts, such as
diacetylenes, bistriazoles, etc. [67]. At the same time, byproduct
formation is catalysed by a base, and the joint utilization of a
basic and an acidic additive is therefore favourable. This buffer
system gives rise to a high reactivity in CuAAC, even at room
temperature (rt), but without byproduct formation [60,67]. This
system thus greatly improves the safety relative to the high-
temperature conditions. The literature data led us to select N,N-
diisopropylethylamine (DIEA) as a base and HOAc as an acid
[67], which were used jointly as additives, each in
0.04 equivalents, at 100 bar and rt as conditions B [60].
As starting materials for the CF CuAAC reactions, azido-substi-
tuted β-aminocyclohexanecarboxylates 11–14 were prepared
previously by a diastereoselective epoxidation of the corres-
ponding 2-aminocyclohexenecarboxylates, followed by a
regioselective oxirane ring opening with NaN3 [68]. Three
different alkynes (phenylacetylene, diethyl acetylenedicarboxy-
late and ethynyl ferrocene) were employed as dipolarophiles to
yield a library of novel 1,2,3-triazole-modified cyclic β-amino
acid derivatives. Compounds 11–14 were racemates, the struc-
tures in Table 1 show their relative stereochemistry. The CF
syntheses were carried out under both conditions A and B in
order to obtain a clear comparison between the performances of
the two approaches. CH2Cl2 was used as a solvent, and the
starting azides were used in a concentration of 0.085 M. A
higher concentration of the starting azides led to the precipita-
tion of the triazole product and a blockage in the CF reactor.
Aliquots of 2.5 mL of a reaction mixture containing 1 equiva-
lent of the azide and 1.5 equivalents of the acetylene were
pumped through the reactor in each run with a a flow rate of
0.5 mL min–1. At this flow rate the residence time on the cata-
lyst bed was as low as 1.5 min and it took only 5 min of process
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Table 1: CF synthesis of 1,2,3-triazole-substituted alicyclic β-amino acid derivatives.
Entry Azidea (1 equivalent) Acetylene (1.5 equivalents) Product Yieldb (%)
Ac Bd
1
11
15
61 96
2
12
16
47 97
3
13 17
33 76(98)e
4
14
18
53 89(98)e
5
11
19
98 97
6
12
20
97 98
7
13 21
97 96
time to pump the 2.5 mL aliquots through the system. This
resulted in around 100 mg of crude product, depending on the
conversion and the molecular masses of the reactants.
In the Cu(I)-catalysed reactions between phenylacetylene and
the azido-substituted β-amino acid derivatives 11–14, 1,4-disub-
stituted 1,2,3-triazole isomers (15–18) were regioselectively
formed. The high-pressure/high-temperature conditions A led to
only medium yields (Table 1, entries 1–4), but under conditions
B the yields of triazoles 15 and 16 were excellent, and those of
triazoles 17 and 18 were high (76% and 89%, respectively;
Table 1, entries 1–4). When the CF reactions of azides 13 and
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Table 1: CF synthesis of 1,2,3-triazole-substituted alicyclic β-amino acid derivatives. (continued)
8
14
22
97 98
9
11
23
95 97
10
12
24
91 98
11
13
25
96 93
12
14
26
75 97
acazide = 0.085 M. bYield of isolated product. cConditions A: CH2Cl2 as solvent, 100 bar, 100 °C, flow rate 0.5 mL min–1, without any additives.
dConditions B: CH2Cl2 as solvent, 100 bar, rt, flow rate 0.5 mL min–1, with 0.04 equivalents of DIEA + 0.04 equivalents of HOAc. eAchieved under the
following conditions: CH2Cl2 as solvent, 100 bar, 100 °C, flow rate 0.5 mL min–1, with 0.04 equivalents of DIEA + 0.04 equivalents of HOAc.
14 with phenylacetylene were repeated under high-pressure/
high-temperature conditions with the simultaneous use of addi-
tives (100 bar, 100 °C, 0.04 equivalents each of DIEA and
HOAc; further conditions were not modified), triazoles 17 and
18 were obtained in very high yields (98% in both cases;
Table 1, entries 3 and 4).
1,4,5-Trisubstituted 1,2,3-triazoles are of notable importance in
drug discovery. For example, several 1,2,3-triazole-4,5-dicar-
boxylates display significant antituberculotic activity in vitro
[69]. Thus, a nonterminal alkyne, diethyl acetylenedicarboxy-
late, was subjected to CF CuAAC with the azido-functionalized
β-amino acid derivatives 11–14 as reaction partners. 1,4,5-
Trisubstituted 1,2,3-triazole dicarboxylates 19–22 were
obtained in excellent yields (>96%) under both conditions A
and B (Table 1, entries 5–8). In this set of CF syntheses, no
significant difference was observed between the performances
of the two methods.
Ferrocene-triazole conjugates play a crucial role in the labelling
and detection of various systems, such as biomolecules, poly-
mers, nanomaterials and supramolecular assemblies [70]. They
also have potential applications in medicinal chemistry and drug
discovery as biosensing probes, in immunoassays and in
host–guest chemistry [71]. Ferrocene-substituted amino acids
have been of significant importance in the investigation of the
secondary structures of different peptides and foldamers [72].
Thus, conjugates of the azido-functionalized β-amino acid
Beilstein J. Org. Chem. 2013, 9, 1508–1516.
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Scheme 2: Gramm-scale CF synthesis of triazole 22 under conditions B.
derivatives 11–14 were prepared with ethynylferrocene as a
dipolarophile. Both conditions A and B afforded ferrocenyltria-
zoles 23–25 in excellent yields (>91%; Table 1, entries 9–11).
However, in the case of ferrocenyltriazole 26 the high-pressure/
high-temperature conditions A led to a yield of only 75%,
whereas the use of additives at rt (conditions B) proved more
efficient, with a yield of 97% (Table 1, entry 12). Triazoles
23–26 were obtained selectively as 1,4-disubstituted regioiso-
mers.
To understand the differences between the results obtained with
the three different dipholarophiles, it must be taken into account
that the carboxylate groups of diethyl acetylenedicarboxylate
and the aromatic system of the ferrocenyl group as ligands can
probably coordinate copper from its matrix. Therefore, the
concentration of the catalytically active Cu(I) species is
increased as compared to the reactions with phenylacetylene
[73-75]. Accordingly, the yields were usually higher in the reac-
tions with diethyl acetylenedicarboxylate and ethynylferrocene
than with phenylacetylene (Table 1, entries 5–12 versus entries
1–4). These differences can mainly be observed between the
results obtained under conditions A. This is because the base, as
an additive, evolves the same effect and improves the reactivity
through the CuAAC, thus in the case of conditions B (the use of
additives) the influence of the alkyne is practically masked.
The presence of trace amounts of copper in the chromatographi-
cally purified triazole products was determined by means of
inductively coupled plasma mass spectrometry (ICP–MS). The
analytical data in Table 2 show that the contents of copper
impurities in the products were appropriately low, i.e., amounts
of 3.9–9.1 µg g–1 were detected. It should be noted that the
samples obtained with the joint use of DIEA + HOAc (condi-
tions B) contained more copper than those obtained under
conditions A (high-temperature/high-pressure without addi-
tives). The levels of copper contamination detected in our tria-
zole products compare well with literature results relating to CF
[50] and conventional batch experiments [76].
In conventional batch-based chemistry, the scale-up of chem-
ical reactions can be a challenge because the output depends on
Table 2: Copper contents in the triazole products after column
chromatographic purification on silica gel.
Entry Product Copper content (µg g–1)a
Ab Bc
1 15 4.6 (±0.5) 8.4 (±0.6)
2 16 4.2 (±0.3) 7.7 (±0.6)
3 17 3.9 (±0.5) 8.0 (±0.4)
4 18 4.7 (±0.6) 8.2 (±0.7)
5 19 5.2 (±0.4) 7.9 (±0.4)
6 20 5.1 (±0.3) 7.5 (±0.6)
7 21 4.8 (±0.6) 7.7 (±0.7)
8 22 5.3 (±0.3) 8.2 (±0.6)
9 23 6.1 (±0.5) 8.6 (±0.5)
10 24 4.8 (±0.4) 7.7 (±0.8)
11 25 5.4 (±0.3) 9.1 (±0.4)
12 26 4.9 (±0.6) 7.8 (±0.7)
aDetermined by ICP–MS. bConditions A: CH2Cl2 as solvent, 100 bar,
100 °C, flow rate 0.5 mL min–1, without any additives. cConditions B:
CH2Cl2 as solvent, 100 bar, rt, flow rate 0.5 mL min–1, with
0.04 equivalents of DIEA + 0.04 equivalents of HOAc.
the batch size. The situation becomes even more complicated
when unstable reactants such as azides are handled on a large
scale. However, the scalability of CF procedures is a straight-
forward function of time and the flow rate, and the risks asso-
ciated with the accumulation of hazardous species are mini-
mized, because the solution of the reactants is eluting continu-
ously from the active zone of the reactor [33,34,44,45,60]. The
CF CuAAC between azide 14 and diethyl acetylenedicarboxy-
late was scaled up in a simple, safe and efficient manner to
achieve gram-scale production (Scheme 2). Methods A and B
proved equally efficient in the small-scale CF syntheses of tria-
zole 22 (Table 1, entry 8). However, we performed the large-
scale experiment at 100 bar and rt in the presence of the addi-
tives (conditions B) so as to ensure maximum safety through-
out the procedure. A CH2Cl2 solution of the reaction mixture
containing 1 equivalent of the azide (cazide = 0.085 M),
1.5 equivalents of the acetylene and 0.04 equivalents of each
additive was pumped continuously through the system at a flow
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rate of 0.5 mL min–1. During the whole scale-up procedure, the
same portion of copper powder was used in the catalyst bed.
The solution of the crude product was collected for 100 min,
and after purification 2.06 g of triazole 22 was obtained, which
is equivalent to a yield of 96%.
Conclusion
Twelve highly functionalized 1,2,3-triazole-substituted
β-aminocyclohexanecarboxylic acid racemates were success-
fully prepared in CF mode as a small library of novel com-
pounds with possible biological effects. The CF syntheses were
first performed under high-pressure/high-temperature condi-
tions with copper powder as a readily accessible Cu(I) source.
Subsequently, to moderate the harsh reaction conditions, the
reaction temperature could be lowered to rt in the presence of
additives. The joint use of a base and an acid dramatically im-
proved the reactivity in the CuAAC, while it completely elimi-
nated unwanted byproduct formation. These conditions ensured
enhanced safety and typically higher yields than those attained
under the harsh reaction conditions. Simple, efficient and safe
gram-scale production was also implemented in a short
processing time, which can be important for potential industrial
applications.
Experimental
General Information
The reagents and materials were of the highest commercially
available purity grade and were used without any further purifi-
cation. Flash column chromatography was performed on Merck
silica gel 60, particle sizes ranged from 63 to 200 μm, and
analytical thin-layer chromatography (TLC) on Merck silica gel
60 F254 plates. Compounds were visualized with UV light or
KMnO4. 1H and 13C NMR spectra were recorded on a Bruker
Avance DRX 500 spectrometer, in CDCl3 as a solvent, with
TMS as internal standard, and at 500.1 and 125.0 MHz, respect-
ively. Microanalyses were performed on a Perkin-Elmer 2400
elemental analyser.
Determination of the copper contents of the
triazole products
Copper concentrations were determined by ICP–MS by using
an Agilent 7700x instrument equipped with a collision cell. The
determination was carried out on the isotope 63Cu, with He as
collision gas. The standard solutions for external calibration
were prepared from a stock solution (Certipur, Merck) by dilu-
tion with doubly deionized water (Millipore MillQ, Merck). All
glassware and plastic utensils used during the determination
were precleaned by soaking in solutions of trace-metal-grade
nitric acid and hydrochloric acid (Suprapur, Merck), followed
by rinsing with copious amounts of doubly deionized water.
General procedure for the CF reactions
An H-Cube® system was used as a CF reactor in the “no H2”
mode. For the CF reactions, the catalyst bed (internal dimen-
sions: 70 mm × 4 mm) was filled with ~900 mg of copper
powder with an average particle size of 200 µm. 70 mg
(0.21 mmol, 1 equivalent) of the corresponding azide and
0.32 mmol (1.5 equivalents) of the alkyne, and (only in method
B) 1.5 µL (0.0084 mmol, 0.04 equivalents) of DIEA and 0.5 µL
(0.0084 mmol, 0.04 equivalents) of HOAc were dissolved in
2.5 mL of CH2Cl2. The solution was homogenized by sonica-
tion, and then pumped through the CF reactor under the appro-
priate conditions. Between two reactions in the CF reactor, the
catalyst bed was washed at rt for 5 min with CH2Cl2 at a flow
rate of 1 mL min–1. The crude product was checked by TLC
with a mixture of n-hexane/EtOAc as an eluent, and the solvent
was next evaporated off under vacuum. Column chromato-
graphic purification was carried out on silica gel with a mixture
of n-hexane/EtOAc as an eluent. The 1,2,3-triazole-modified
compounds were characterized by elemental analysis and NMR
experiments. For detailed analytical data see Supporting Infor-
mation File 1.
Measurement of the residence time on the
catalyst bed
To determine the residence time, a CH2Cl2 solution of a blue
ink was pumped through the catalyst bed. The time that elapsed
between the first contact of the ink with the bed and the moment
when the blue colour appeared at the column outlet was
measured.
Supporting Information
Supporting Information File 1
Detailed analytical data of the prepared compounds and a
collection of NMR spectra.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-9-172-S1.pdf]
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